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A modern approach to the treatment of plaque psoriasis
Psoriasis is a common chronic inflammatory skin dise-
ase which affects 0.5–1 % of children and 2–3 % of the 
adult population. In Croatia, 1.6 % of the population 
suffer from psoriasis. Distribution of the disease is bi-
modal, with the first peak at the age of 20–30, and the 
second at the age of 50–60. The etiopathogenesis of the 
disease is multifactorial, the key factors being genetic 
predisposition combined with immunological disor-
ders, environmental factors and skin barrier damage. 
There are several clinical variants of the disease. The 
main signalling pathways in psoriasis include TNF-α, 
IL-23 and IL-17. Topical agents are used for the treat-
ment of the mild form, and the systemic conventional 
therapy is used for the treatment of moderate to severe 
forms of the disease. In cases where’s no response, or 
intolerance or contraindications are present, new tar-
geted medications are to be administered. Develop-
ment in the field of immunogenetics of psoriasis leads 
to personalized medicine.
Keywords: psoriasis, topical treatment, conventional 
systemic therapy, small molecules, biologicals
Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of 
children and 2–3 % of the adult population (1). It affects approximately 125 million people 
in the world. Prevalence ranges from 0.91 % in the USA to 8.5 % in Norway (2). Prevalence 
patterns vary across the world. In line with the beneficial effects of the UV radiation, there 
are fewer cases of psoriasis in countries closer to the equator compared to the countries 
that are further away. 
In Croatia, approximately 70,000 people suffer from psoriasis, which represents 1.6 % 
of the population (3). Distribution of the disease is bi-modal, with the first peak at the age 
of 20–30, and the second at the age of 50–60. Despite the improvements in therapy and 
consequently in life-expectancy, patients affected by psoriasis are still more likely to die 
prematurely (4).
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The etiopathogenesis of the disease is multifactorial, the key factors being genetic 
predisposition combined with immunological disorders, environmental factors and skin 
barrier damage. Environmental factors that have been identified so far are drugs (imiqui-
mod, lithium, beta blockers, IFNs and even anti-TNFs), infections (streptococcal throat 
infections), a physical trauma (Koebner phenomenon), smoking, alcohol and stress (5). 
Psoriatic lesional skin has increased levels of S. pyogenes and S. aureus compared to non-
lesional and healthy skin (1). Psoriasis is a complex disease with more than 30 single nu-
cleotide polymorphisms contributing to the risk of the disease (6). Two gene mutations, 
that can induce psoriasis independently (IL-36RN and CARD14), have been identified. 
There are at least 12 major PSORS psoriasis susceptibility loci identified (6). More than 60 % 
of patients suffering from psoriasis carry the HLA Cw0602, the disease loci associated 
haplotype (1). If one of the parents has psoriasis, their children have a 20 % chance of de-
veloping the disease, whereas if both of the parents are affected, the risk rises to 65 % (1). 
There is a 70 % probability of monozygotic twins to be affected by psoriasis and 20 % for 
dizygotic twins (1).
Nowadays, psoriasis is considered a systemic inflammatory disease and not just a 
skin disease. The notion of psoriatic march describes the cutaneous inflammation leading 
to a cascade of events that increases the risk of CVD in patients with severe psoriasis (2). 
There is a strong association between psoriasis and cardio-metabolic diseases, gastrointes-
tinal diseases kidney disease, malignancy, infection and mood disorders. Furthermore, 
there are studies that point out the emerging comorbidities such as obstructive pulmonary 
disease, peptic ulcer, sexual dysfunction and sleep apnea. Some studies suggest that pso-
riasis is an independent risk factor for MACE (MI, stroke, death to CVD) (7). Lymphoma is 
also associated with psoriasis. This can be attributed to the pathophysiology of psoriasis 
or its treatment since methotrexate and cyclosporine have been associated with lymphoma. 
Patients with psoriasis have an increased risk of squamous cell carcinoma because of certain 
psoriatic treatments such as PUVA (8).
There are several clinical variants of the disease out of which the most important are 
chronic plaque psoriasis (85–90 %), eruptive guttata psoriasis, pustular psoriasis and 
erythrodermic psoriasis (5) (Fig. 1–3).
Chronic plaque psoriasis is characterized by well-demarcated erythematous plaques 
with adherent silver scales (9). Psoriasis guttata (or eruptive psoriasis) is a form of psoriasis 
usually preceded by streptococcal infection of the upper respiratory tract and is characte-
rized by numerous tiny erythematosquamous lesions, the size of a droplet (10). One third 
of children affected by this form of psoriasis develop plaque psoriasis later in life (11).
Generalized pustular psoriasis is a rare but life-threatening disease. It is characterized 
by the episodic appearance of sterile pustules together with widespread skin and sys-
temic inflammation (5). An erythrodermic psoriasis is a form of psoriasis marked by gene-
ralized erythema and exfoliation. This is a potentially life-threatening condition with sys-
temic manifestations such as hypothermia, oedema, myalgia and malaise. It can be 
provoked by abrupt withdrawal of drugs like methotrexate or corticosteroids from the 
therapy (11).
Psoriatic arthritis affects between 1.3 and 34.7 % of patients diagnosed with psoriasis. 
The clinical symptoms vary with the most common being enthesitis, peripheral arthritis, 
spondylitis, dactylitis (Global report) and arthritis mutilans (12).
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Fig. 1. Clinical presentation of plaque psoriasis: a) on the back, b) on the palms, c) on the trunk. The 
patient gave written consent to the authors for the use of these photographs.
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Psoriasis is a highly visible condition and patients have to endure social stigma due to 
the nature of the disease (2). They feel ashamed and guilty, the disease has a detrimental 
effect on their interpersonal relationships, sexual well-being and capacity for intimacy (1).
The severity of the disease is associated with a higher level of systemic inflammation. 
Psoriasis shares many inflammatory processes and predisposing factors with its comor bi-
dities and associated diseases (7).
Today, it is widely accepted that the main signalling pathways in psoriasis include 
TNF-α, IL-23 and IL-17. It has been established that different cytokines dominate in various 
clinical presentations of psoriasis, e.g. interferon γ dominates in the acute erythrodermic 
psoriasis, TNF-α, IL-23/IL-17 in the chronic plaque psoriasis, and IL-36/IL-1 in pustular 
psoriasis (13). The TNF-α-IL-23-Th17 axis seems to be pivotal in the pathogenesis of plaque 
psoriasis. Aberrant dermal dendritic cells produce TNF-α and IL-23 which stimulate Th17 
and Tc17 cells to migrate into the epidermis where they identify epidermal autoantigens 
and start producing IL-17 and IL-22 (13).
Additional important effector cells such as neutrophils, mast cells and monocytes, media-
tors and potential autoantigens are being investigated as a possible new targeted therapy.
Melanocytes, but not the keratinocytes, have been identified as target cells of an HLA-
-Cw6 restricted CD8 T cell clone found in the psoriatic plaques (14).
Before selecting the treatment, it is necessary to establish the severity of the disease. 
When estimating the severity of chronic plaque psoriasis, three scales are commonly used 
and those are: PASI score (psoriasis area and severity index), BSA (body surface area) and 
DLQI (dermatological quality of life index). PASI score is the most commonly used method 
for the evaluation of the severity of the disease on a scale from 0 to 72. This method takes 
into account the skin surface covered with psoriatic lesions as well as the degree of ery-
thema, induration and desquamation of the lesions. BSA is a method used to establish the 
percentage of skin covered with psoriatic lesions. DLQI is a scale which is used to estimate 
the effect of psoriasis on the patient’s everyday life, social interaction and his overall well-
being. 
According to the guidelines, mild psoriasis is defined by PASI and/or BSA and/or 
DLQI levels equal or less than 10, and moderate and severe psoriasis have PASI and/or BSA 
and/or DLQI levels exceeding 10 (3).
Topical therapy
Topical agents are used for the treatment of the mild form of the disease. 
Emollients keep the skin moist and soft, thus minimizing the itching, tenderness or 
subsequent development of psoriatic lesions at the sites of potential trauma. They are an 
important addition to psoriasis treatment (15). 
Mid to high-potency topical corticosteroids reduce inflammation rapidly and induce 
regression of lesions, especially when applied under occlusion. Long-term treatment can 
lead to skin atrophy, telangiectasia or stretch marks. Topical corticosteroids can be applied 
in intermittent regimen in patients with quick recurrence of psoriatic lesions. Non-fluori-
nated corticosteroids are used for facial, genital and intertriginous lesions (15, 16).
Calcineurin inhibitors. Although not officially approved, both tacrolimus ointment 
and pimecrolimus cream have proven to be helpful in the treatment of intertriginous and 
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facial psoriasis. They penetrate well in the skin folds and the risk of prolonged corticoste-
roid use is avoided. Possible risk of lymphoma and skin cancer in patients on topical calci-
neurin inhibitors was reported but subsequent studies have not confirmed it (17).
Vitamin D analogues calcipotriol and tacalcitol reduce the proliferation of keratino-
cytes and modulate T cell and dendritic cell function. Combination of calcipotriol and 
potent corticosteroids has shown better clinical results and tolerance compared with either 
agent used as a monotherapy (18).
Tars and dithranol are used less frequently nowadays, as well as topical retinoids such 
as tazarotene. 
Along with topical drugs, phototherapy and different forms of systemic therapy such 
as retinoids, methotrexate and cyclosporine are used for the treatment of moderate to se-
vere psoriasis (3).
Photo- and photochemotherapy
In patients who do not respond adequately to local therapy, narrow band (311 nm wave-
length) UVB phototherapy is a good treatment option (3, 15, 19). The initial dose of UVB light 
is determined by the skin phototype and/or minimal erythema dose. The dose is gradually 
increased during the therapy. This treatment is usually administered 3 to 5 times per week 
for 3 to 4 weeks. It is especially effective in treating psoriasis guttata (20, 21).
PUVA photochemotherapy combines UVA irradiation and photosensitizer psoralen. 
It induces the remission of psoriasis by repeated controlled phototoxic reactions. Psoralen 
is a furocoumarin, which is found in many plants. Psoralen molecules intertwine with 
DNA strands and, when exposed to UVA, form DNA adducts and thus inhibit cell prolife-
ration. They can be used systemically, topically and as bath therapy (16). The initial dose 
of UVA light is determined by the skin phototype and/or the minimal phototoxic dose. The 
treatments are administered up to four times per week during three to four weeks. Chronic 
adverse effects include increased risk of squamous cell carcinoma, skin ageing and the 
development of PUVA lentigines and even melanoma (16).
Conventional systemic therapy
Retinoids – acitretin is an aromatic retinoid, a derivative of vitamin A, with anti-
proliferative and anti-inflammatory effect. In treating plaque psoriasis, retinoids are nowa-
days usually combined with UVB (Re-UVB) or PUVA (Re-PUVA) in order to increase the 
effect of phototherapy and to decrease the exposure to UV-light. As monotherapy for 
plaque psoriasis, acitretin is prescribed in a daily dose of 20–50 mg for 2 to 4 weeks (or 
more if needed), regardless of the patient’s weight. The standard dose for the treatment of 
psoriatic erythroderma is 0.25 to 0.5 mg kg–1, and for pustular psoriasis 0.75 to 1 mg kg–1. 
Maintenance dose for all types of psoriasis is 0.125–0.5 mg kg–1 (22). The side effects of 
acitretin are dose-related and are almost always reversible upon the drug withdrawal. The 
most common side effects are dryness of the lips, cheilitis, and dryness of other areas of 
the skin, eyes and of the nasal mucosa. Night vision might be disturbed. Effluvium might 
occur. In around half of the patients elevated cholesterol and triglyceride levels are re-
ported and in about 25 % of liver function tests are abnormal. Rare adverse changes com-
prise bone and joint pain and elevated intracranial pressure. The main contraindication to 
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the use of acitretin is pregnancy, due to its teratogenicity. In case of use in women of 
childbearing potential, pregnancy test as well as reliable contraceptive measures must be 
administered during therapy and two to three years after discontinuing the drug (22).
Methotrexate is the folic acid antagonist. It is effective as long-term therapy for both 
psoriasis and psoriatic arthritis. Methotrexate inhibits the enzyme dihydrofolate reduc-
tase which leads to inhibition of purine synthesis. In lower doses, it induces the apoptosis 
of activated T cells, and at higher it blocks the DNA synthesis and cell proliferation. Metho-
trexate is administered orally or subcutaneously once a week. The initial dose is 7.5 mg per 
week. This can be gradually elevated up to the maximum dose of 25 mg (22). The acute side 
effects of methotrexate include erosions on the oral mucosa, gastrointestinal problems 
such as diarrhea, bleeding, ulcers, bone marrow suppression (thrombocytopenia, leuko-
penia, anemia) and effluvium. Chronic side effects might include pulmonary fibrosis, 
hepatotoxicity, chronical renal impairment and troubles with spermatogenesis. Absolute 
contraindications to its use are severe infections, bone marrow suppression, pregnancy, 
peptic ulcer, alcoholism, and impaired liver function (22).
Cyclosporine is a highly and rapidly effective cyclic polypeptide, a calcineurin inhi-
bitor which inhibits T cell activation and IL-2 cytokine production. The recommended 
initial dose is 2.5 mg kg–1. This level can be continued if the patients show improvement 
after one month of treatment, but if not, the dose can be elevated to 5 mg kg–1 (22). Cyclo-
sporine is used for the treatment of pustular psoriasis as well but in a higher initial dose. 
It is seen as an interventional therapy and is not recommended for long-term treatment. 
The lowest possible maintenance dose should be used. Cyclosporine can cause renal im-
pairment, with increased creatinine and potassium levels and decreased glomerular filtra-
tion rate. Renal vascular damage might occur and it is irreversible. Other common adverse 
 effects are gingival hyperplasia, hypertrichosis and tremor (16). Contraindications include 
hypersensitivity to cyclosporine, malignancies other than epidermal carcinomas, unregu-
lated hypertension, renal impairment, severe infections and concomitant PUVA therapy 
(19).
Dimethyl fumaric esters are licensed as the induction therapy for moderate to severe 
psoriasis in Germany (23). Their mechanism of action seems to be immunomodulatory, 
inducing apoptosis of activated T cells and alteration of the cytokine secretion. The initial 
dose of 0.2 mg per day is slowly increased to avoid the severity of side effects such as flush-
ing, nausea, vomiting and heartburn. The maximum dose is 1.2 mg per day, but most pa-
tients require 0.4 to 0.8 mg. During the first week, eosinophilia appears, whereas later on 
lymphopenia develops. Proteinuria is a serious adverse effect (16, 22). 
If patients, suffering from moderate to severe psoriasis, do not respond, cannot tolerate 
or have a contraindication for the conventional systemic therapy (PUVA, retinoids, metho-
trexate, cyclosporine), they become candidates for the administration of new targeted 
medications such as small molecules and biologics, according to the European or local 
guidelines (19, 23).
Targeted therapies – Small molecules
Apremilast is an oral medication used for the treatment of moderate to severe plaque 
psoriasis. By increasing the level of cAMP, this phosphodiesterase-4 inhibitor reduces the 
production of various mediators that play a crucial role in the development of psoriasis 
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(24). The standard dosage is 30 mg twice daily after 6 days of gradually increasing the 
 dosage. Apremilast appears to be effective for nail psoriasis and for palmoplantar and scalp 
psoriasis (25). This drug is also effective in psoriatic arthritis. PASI 75 response is achieved 
in 33 % of patients in the sixteenth week of the treatment. It is shown as a relatively safe 
and effective treatment in the combination with systemic, biologic or phototherapy in the 
treatment of chronic plaque psoriasis, reflected by achieving PASI 75 (26). Recommended 
laboratory controls include complete blood count, liver enzymes and renal function. Apre-
milast has a very good safety profile due to its non-immunosuppressive mechanism of 
action (26). Diarrhea is the most common side effect, whereas others include vomiting, 
dyspepsia, abdominal pain, upper respiratory infections, fatigue, insomnia, migraine, 
weight loss (23). The most severe side-effect is depression, including suicidal ideation (22).
Targeted therapies – Biologics
Medications that specifically target TNF-α, IL-23/IL-12, IL-17 and IL-23 are currently 
available (Table I). Biologics are generally well tolerated and mostly used as a monotherapy. 
TNFα inhibitors are effective in both psoriasis and psoriatic arthritis. Suggested controls 
include blood count, liver enzymes, CRP, creatinine, urine analysis. Prior to the therapy, 
initiation pregnancy test, HBV, HCV, HIV and tuberculosis screening including chest X-ray 
is advised. Breastfeeding, demyelinating disease, active chronic hepatitis B, active tuber-
culosis, localized infections and congestive heart failure (NYHA III/IV) are absolute contra-
indications for the administration of TNFα inhibitors. Injection site reactions, infections, 
bone marrow suppression, demyelinating disease, drug-induced lupus, lymphoma and 
solid malignancies are possible adverse events. Formation of antibodies against anti TNFs 
might reduce the response to therapy (27). Combination with methotrexate might prevent 
the formation of antibodies (19).
Adalimumab, initially used for treating patients suffering from rheumatoid arthritis, 
is a humanized monoclonal antibody targeting TNFα. The initial dosage is 80 mg sub-
cutaneously, followed by 40 mg every two weeks, starting one week after the first dose (19, 
22). The clinically significant response is expected after four weeks. PASI 75 is achieved in 
53–80 % patients. Formation of antibodies against adalimumab is reported in 6 to 50 percent 
of patients treated which might reduce the response to the therapy (27). Adalimumab 
 biosimilars comprise adalimumab-atto and adalimumab-admb. A randomized trial that 
compared adalimumab with adalimumab-atto in 350 patients with moderate to severe 
psoriasis showed similar efficacy and safety after 16 weeks of treatment in both treatment 
groups (28).
Infliximab is a chimeric monoclonal antibody against TNF-α. It has a faster onset of 
action compared to other commercially available biologic agents. The recommended dos-
age is 5 mg kg–1 administered in intravenous infusion at weeks 0, 2 and 6 and every eight 
weeks subsequently (19, 21). A clinically significant response is expected after 1 to 2 weeks. 
About 80 % of patients achieve PASI 75, ten weeks after therapy initiation. Anti-infliximab 
antibodies have been reported in 5 to 55 percent of patients who receive infliximab (29). 
Switching to infliximab-dyyb, a biosimilar to infliximab is not inferior to the original 
 therapy (30).
Etanercept is the antagonist of the TNF-α receptor. The standard dosage for etaner-
cept is 25 mg twice a week or 50 mg once a week. In overweight patients or in severe pso-
riasis 50 mg can be given twice a week up to three months, followed by a dose of 25 mg 
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twice a week or 50 mg once a week (19, 22). PASI 75 is achieved in 33 or 49 % of patients 
after 12 weeks. The formation of anti-etanercept antibodies has been reported, but unlike 
the antibodies against adalimumab and infliximab, they do not seem to reduce the efficacy 
of the treatment (27).
IL-12/IL-23 inhibitors. Ustekinumab is a human monoclonal antibody that targets p40 
subunit shared by IL-12 and IL-23. Dosage of ustekinumab is weight-based. The recom-
mended dosage for adults weighing ≤ 100 kg is 45 mg ustekinumab given at weeks 0, 4, and 
every 12 weeks thereafter. A 90 mg dosage is recommended for adults weighing > 100 kg. 
Ustekinumab can also improve psoriatic arthritis (19, 22). This medication showed PASI 75 
response in 75 % of the patients who received 45 mg and in 69 % who received 90 mg (31). 
Risk of major adverse cardiovascular events was detected in early phase clinical trials with 
ustekinumab. However, subsequent larger trials have not confirmed this finding (32, 33). 
Possible side effects include headache and nasopharyngitis. Anti-ustekinumab antibodies 
have been reported in 4 to 6 patients treated, but the effect of the antibodies on the treat-
ment efficacy is yet to be established (27).
IL-17 targeted therapies are effective in both psoriasis and psoriatic arthritis. In pa-
tients treated with IL-17 inhibitors, the development or exacerbation of inflammatory 
bowel disease have been noticed (34). Candida infections are more common under this 
treatment (13). 
Secukinumab is an anti-IL-17A monoclonal antibody. The standard dosage is 300 mg 
subcutaneously once a week at weeks 0, 1, 2, 3 and 4 and every four weeks thereafter (23, 
34). Dosage of 150 mg is adequate for some of the patients. 
Ixekizumab is a humanized monoclonal antibody against IL-17A. The standard dos-
age for ixekizumab is 160 mg at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, 12 and 
every four weeks thereafter (15).
Brodalumab is an anti-IL-17 receptor A monoclonal antibody. The recommended dos-
age is 210 mg given at weeks 0, 1, and 2 and then every two weeks (15).
IL-23 targeted therapies. Guselkumab is a human immunoglobulin G1 lambda mono-
clonal antibody that targets p19 subunit of IL-23. The standard dose is 100 mg at weeks 0, 
4 and every eight weeks thereafter. Its efficacy for psoriatic arthritis is still under evalua-
tion. At week 16, PASI 75 response was achieved in 85.1 % and PASI 90 in 73.3 % of patients 
(35). Common adverse events include upper respiratory infections, tinea and herpes sim-
plex infections, arthralgia, diarrhea and gastroenteritis. 
Tildrakizumab is a human immunoglobulin G1 kappa monoclonal antibody targeting 
p19 subunit of IL-23. The standard dose is 100 mg subcutaneously at weeks 0, 4 and every 
twelve weeks thereafter. It has demonstrated a 74 % PASI 75 and 52 % PASI 90 response in 
the sixteenth week of therapy (36).
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody se-
lective to IL-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA 
technology. It has shown 88 % PASI 75, 81.5 % PASI 90 and 48 % PASI 100 at week 12. De-
spite having received the last injection at week 16, 26 % of patients remained clear after 48 
weeks (PASI 100) (37).
Targeted therapies in special patient populations: biologics should be avoided during 
pregnancy, anti-TNFs should be discontinued 1 to 2 weeks before surgery and can be re-
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sumed after 1 to 2 weeks after, live vaccines are contraindicated, biologics should be avoid-
ed in patients with active malignancy and lymphoma (13). The following biologics are 
approved for the use in children: etanercept (from 6 years of age), ustekinumab (from 12 
years of age) and adalimumab (from 4 years of age) (38). Certolizumab pegol is considered 
safe for use in pregnancy and breastfeeding (38).
Therapeutic goals
According to the treatment guidelines, PASI 75 is still the gold standard (19, 22, 23). 
However, as new therapies show higher efficacy and patient expectations became higher, 
today PASI 90 (almost clear skin) and PASI 100 (clear skin) are becoming new treatment 
targets. These new targets are associated with the improvement in the patient’s quality of 
Table I. Biologics approved for psoriasis





25 mg twice a week or 50 mg once a 
week. In overweight patients or in severe 
psoriasis 50 mg can be given twice a 
week up to three months, followed by a 
dose of 25 mg twice a week or 50 mg 
once a week
+
Infliximab TNF-α intra-venous 5 mg kg
–1 on week 0,2 and 6, then every 
8 weeks +
Adalimumab TNF-α subcutaneous
80 mg initial dose, then 40 mg every 2 
weeks, starting one week after the 
initial dose
+
Ustekinumab IL-12 / IL-23 p40
subcutaneous 45 mg ( 100kg) or 90 mg (> 100 kg) on 
week 0 and 4, then every 12 weeks +
Secukinumab IL-17A subcutaneous 300 mg on week 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks +
Ixekizumab IL-17A subcutaneous 160 mg week 0, then 80 mg week 2, 4, 6, 8, 10, 12, then 80 mg every 4 weeks +
Brodalumab IL-17A receptor subcutaneous
210 mg on week 0, 1, and 2, then every 2 
weeks +
Guselkumab IL-23 p19 subcutaneous 100 mg at weeks 0, 4 then every 8 weeks 
Tildrakizumab IL-23 p19 subcutaneous 100 mg subcutaneously at weeks 0, 4 and then every 12 weeks
Risankizumab IL-23 p19 subcutaneous
150 mg (two 75 mg injections) adminis-
tered by subcutaneous injection at week 
0, week 4, and then every 12 weeks
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life (39). Group of authors suggest cut-off of „5“ for both PASI and DLQI, where dermatolo-
gists should consider changing the treatment if the target is not achieved (14). The aim of 
the treatment is to prevent progression or development of comorbidities and to control 
systemic inflammation (40).
Treatment of patients with psoriasis and comorbid conditions
For patients with psoriasis and psoriatic arthritis, TNF inhibitors are the suggested 
first option. If there is no response, IL-17 inhibitors should be considered. If arthritis is 
mild and psoriasis severe, ustekinumab might be the option. In patients with psoriasis and 
multiple sclerosis, ustekinumab and IL-17 inhibitors are the right treatment option, while 
TNF inhibitors should be avoided, due to possible worsening of the disease. Patients with 
psoriasis and congestive heart failure can be treated with ustekinumab and IL-17 inhibi-
tors, while all TNF inhibitors should be avoided. In patients with psoriasis and inflamma-
tory bowel disease adalimumab, infliximab and ustekinumab would be the best treatment 
option. Ustekinumab is still considered the first option for patients with psoriasis and 
hepatitis B. IL-17 inhibitors should be considered as the second option. TNF inhibitors 
reduce host immune defences and might allow reactivation of hepatitis B. Therefore, TNF 
inhibitors are considered as a third option. Before initiating the TNF inhibitors, screening 
for hepatitis B should be performed. Vaccination is recommended to all non-immune patients. 
Screening for latent tuberculosis infection should be performed in all patients planned for 
biologics. Anti-TB prophylaxis for a minimum of 1–2 months should be provided to all of 
the patients before initiating the therapy. The first option for this patient group is 
ustekinumab followed by IL-17 inhibitors and anti-TNFs as the last option (38).
CONCLUSIONS
Some authors suggest the term moderate psoriasis should be reintroduced and small 
molecules, such as apremilast or dimethyl fumaric esters, might be considered as an ideal 
first-line therapy for patients with moderate psoriasis, whereas biologics might be regarded 
as a first-line therapy for severe psoriasis (14). Many studies have given us an insight into the 
coexistence of psoriasis and other serious systemic diseases. An interdisciplinary approach 
of different specialities is needed for the diagnosis and treatment of comorbidities and 
 associated diseases. Comorbidities and associated diseases have a direct influence on 
 dermatologist’s decision regarding the treatment of a patient with psoriasis. The choice of 
the treatment is based on the safety profile of the treatment, patient’s comorbidities and 
special indication profile (13). Developments in the field of immunogenetics of psoriasis 
enable new research of different forms of targeted therapy which could enable persona lised 
medicine. The goal of individualised treatment is the best possible response to therapy and 
the best possible safety profile. Implementation of personalized medicine is possible because 
different biomarkers have been identified by genetic and epigenetic testing. They correlate 
with the severity of the disease (HLA Cw*0602 is associated with early onset and severe 
form of psoriasis), they monitor the efficacy of therapy in relation to the pathogenetic 
mechanism (IL-23/IL-17 axis), and they predict the treatment efficacy (TNFAIP3 gene and 
response to anti-TNF therapy, or HLA Cw*0602 and ustekinumab) (41).
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